With a newly minted approval in hand for Qsymia, Vivus is ready to start the battle for top obesity drug with Arena's Belviq. Will Vivus' likely first-to-market status help, or will Belviq have the upper hand because of Qsymia's labeling? Watch and find out what it all means for investors.
Without a marketing partner, there's already speculation that Vivus could be a buyout candidate, but investors shouldn't put all of their eggs in a basket of explosive growth stocks -- no matter how good the story seems. For instance, the Dow is loaded with companies with solid dividend payouts and highly sustainable business models built for the long haul. The stocks highlighted in The Motley Fool's new special free report, "The 3 Dow Stocks Dividend Investors Need," all have an X factor that makes them stand out from their illustrious Dow peers and could make a nice complement to riskier growth stocks. Download it now, for free.
